According to the lawsuit, defendants misrepresented and/or failed to disclose that:
- the design of uniQure’s Pivotal Study (a study of uniQure’s leading drug candidate in patients with Huntington’s Disease)— including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the U.S. Food and Drug Administration (the “FDA”);
- defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its Biologics License Application (“BLA”) timeline to perform additional studies to supplement its BLA submission; and
- as a result, defendants’ statements about uniQure’s business, operations, and prospects lacked a reasonable basis.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
